Trials / Completed
CompletedNCT03035032
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Astellas Pharma Singapore Pte. Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leuprolide | Subcutaneous Injection |
Timeline
- Start date
- 2017-06-23
- Primary completion
- 2019-11-19
- Completion
- 2019-11-19
- First posted
- 2017-01-27
- Last updated
- 2024-11-26
- Results posted
- 2020-12-09
Locations
19 sites across 8 countries: Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03035032. Inclusion in this directory is not an endorsement.